3281 related articles for article (PubMed ID: 25811419)
1. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
3. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
5. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
Aslam AA; Higgins C; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD012040. PubMed ID: 28102546
[TBL] [Abstract][Full Text] [Related]
6. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.
Aslam AA; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD012040. PubMed ID: 36866921
[TBL] [Abstract][Full Text] [Related]
7. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
8. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
10. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
[TBL] [Abstract][Full Text] [Related]
11. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS;
N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
[TBL] [Abstract][Full Text] [Related]
14. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
15. Macrolide antibiotics (including azithromycin) for cystic fibrosis.
Southern KW; Solis-Moya A; Kurz D; Smith S
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD002203. PubMed ID: 38411248
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
18. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
[TBL] [Abstract][Full Text] [Related]
19. Nebulised hypertonic saline for cystic fibrosis.
Wark P; McDonald VM
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001506. PubMed ID: 30260472
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
